By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



100 Cumming Center, Suite 151-B
Suite A225
Beverly  Massachusetts  01915  U.S.A.
Phone: 978-236-8717 Fax: 978-921-6564


Company News
Cellceutix (CTIX) Files Motion To Dismiss Complaint Filed By The Rosen Law Firm 2/12/2016 9:24:52 AM
Cellceutix (CTIX) Meets With FDA For Phase 2 Clinical Trial Of Kevetrin For Ovarian Cancer 2/11/2016 10:19:45 AM
Cellceutix (CTIX) To Submit Special Protocol Assessment Request To FDA For Phase 3 Clinical Study Of Antibiotic Brilacidin For ABSSSI 2/9/2016 10:24:31 AM
Cellceutix (CTIX) Phase 2 Trial Of New Oral Treatment For Psoriasis Nearing Completion 1/25/2016 12:05:59 PM
Cellceutix (CTIX) Releases Data Used In Receiving FDA Orphan Drug Designation Of Kevetrin For Pancreatic Cancer 1/22/2016 10:44:30 AM
Cellceutix (CTIX) Receives FDA Orphan Drug Designation For Kevetrin For The Treatment Of Pancreatic Cancer 1/21/2016 11:20:30 AM
Cellceutix (CTIX) Submits Briefing Book For Phase 2 Trial Of p53 Targeting Drug For Ovarian Cancer 1/19/2016 10:59:56 AM
Brilacidin Lyophilized As Cellceutix (CTIX) Prepares To Bring First New Class Of Antibiotic To Phase 3 Trials In More Than 20 Years 1/14/2016 10:07:44 AM
Cellceutix (CTIX) Comes Out Swinging After Anonymous Seeking Alpha Blog Post 8/7/2015 7:19:29 AM
IRB Approves Additional Enrollment In Cellceutix (CTIX)'s Clinical Trial Of New Cancer Drug Candidate For Solid Tumors 5/22/2015 11:08:02 AM